Vitiligo: A good prognostic factor in melanoma?

Dermatology Online Journal

Volumn 15, Issue 2, 2009, Pages

  Cunha, Daniela ^a   Assis Pacheco, Fernando ^a   Cardoso, Jorge ^a  

^a HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON;

AGED; ANAMNESIS; ARTICLE; ASTHENIA; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPHADENECTOMY; MELANOMA; MYALGIA; NAUSEA; PROGNOSIS; SKIN METASTASIS; VITILIGO; CANCER INVASION; CANCER STAGING; IMMUNOHISTOCHEMISTRY; LETTER; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY; REOPERATION; RISK ASSESSMENT; SKIN TUMOR; TUMOR RECURRENCE;

AGED; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERONS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REOPERATION; RISK ASSESSMENT; SKIN NEOPLASMS; VITILIGO;

EID: 61849183112     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Boasberg P, Hoon D, Piro L et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol, 2006;126:2658-2663. [PubMed]
2. Schallreuter KU, Levening C, Berger J. Vitiligo and cutaneous melanoma - A case study. Dermatologica, 1991;183:239-45. [PubMed]
3. Le Gal FA, Avril MF, Bosq J et al. Direct evidence to support the role of antigen-specific CD8+ T cells in melanoma-associated vitiligo. J Invest Dermatol, 2001;117:1464-1470. [PubMed]
4. Uchi H, Stan R, Turk MJ et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol, 2006;90:215-241. [PubMed]
5. Daneshpazhooh M, Shokoohi A, Dadban A et al. The course of melanoma-associated vitiligo: a report of a case. Melanoma Res, 2006;16(4):371-3. [PubMed]
6. Wankowicz-Kalinka A, Le Poole C, van den Wijngaard R et al. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res, 2003;16(3):254-60. [PubMed]
7. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Eng J Med, 2006;354:709-18. [PubMed]
8. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001;34:65-77. [PubMed]
9. Ongenae K, Van Geen N, Naeyaert J. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res, 2003;16:90-100. [PubMed]
10. Lengagne R, Le Gal FA, Garcette M et al. Spontaneous vitiligo in an animal model for human melanoma: role of tumor specific CD8+ Tcells. Cancer Res, 2004;64:1496-1501. [PubMed]
11. Garbelli S, Mantonvani S, Palermo B et al. Melanocyte-specific cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res, 2005;18(4):234-42. [PubMed]
12. Luiten RM, Kueter EW, Gallee MP et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cell in metastatic melanoma patients. J Clin Oncol, 2005;23:8978-91. [PubMed]
13. Balch C, Soong S, Ross MI et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann Surg Oncol, 2000;7(2):87-97. [PubMed]
14. Balch C, Soong S, Atkins M et al. An Evidence-based Staging System for Cutaneous Melanoma. CA Cancer J Clin, 2004;54:131-149. [PubMed]
15. Dessureault S, Soong SJ, Ross MI et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001;8(10):766-770. [PubMed]